New study checks cancer Drug's effect on common medications

NCT ID NCT07340190

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The goal is to gather information for safer drug use, not to treat the cancer itself.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANCIES

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Novartis Investigative Site
RECRUITING

Candiolo, TO, 10060, Italy
Novartis Investigative Site
RECRUITING

Pozuelo de Alarcón, Madrid, 28223, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08023, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28040, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28050, Spain